Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.

Aldeyra Therapeutics (ALDX) announced that the U.S. Food and Drug Administration or FDA has accepted for review the resubmitted New Drug Application NDA for topical ocular reproxalap, a first-in-class ...

Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals ...

Deluxe , a Trusted Payments and Data Company, has announced an inducement grant in connection with the recent hiring of Kimberly D. Cross as its Senior Vice President, Chief Human Resources Officer.

Rockwell Automation, Inc. , the global leader in industrial automation and digital transformation, today announces the opening of its 33rd annual Automation Fair® in Anaheim, California. This ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off. The Massachusetts-based biotech said a ...